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The goal of this study was to investigate differences in tear peptidome/proteome proﬁles of
aqueous-deﬁcient dry eye, Meibomian gland dysfunction and control individuals. Tears from
93  individuals were collected by capillary and subjected to solid-phase extraction followed
by  MALDI-TOF for proﬁling analysis.
Obtained spectra were aligned by variable penalty dynamic time warping (VPdtw) and
the resulting data analyzed using multivariate statistics. Comparative analyses revealed
good  performance of VPdtw and a high discrimination of groups with a correct assignment
of  89.3% using twelve informative peaks. SDS–PAGE followed by MALDI-TOF/TOF analysis
allowed identiﬁcation of lipocalin-1 as a biomarker candidate.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European ProteomicsTears
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(http://creativecommons.org/licenses/by-nc-nd/3.0/).
disorders (SOSD), such as allergic eye disease, chronic non-dry
eye conjunctivitis, infective conjunctivitis, keratoconjunctivi-1.  IntroductionDry eye (DE) is understood as a complex syndrome which is
frequently associated with other symptomatic ocular surface
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tis and Meibomian gland dysfunction (MGD) among others [1].
Frequently, some of these diseases may coexist and interact
 European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/3.0/).
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n the same patient. MGD  and these other conditions may
ause or contribute to dry eye, but exist in their own right
s either symptomatic or asymptomatic disorders. In general,
ry eye is classiﬁed in two subtypes, aqueous-deﬁcient (ADDE),
n which a failure of lacrimal secretion occurs, and evapora-
ive dry eye (EDE), caused by an excessive water loss from the
xposed ocular surface [2], with MGD  being the main cause of
his last type of dry eye [3]. MGD  is a subtype of posterior ble-
haritis, which is deﬁned as chronic, diffuse abnormality of
he Meibomian glands, commonly characterized by terminal
uct obstruction and/or qualitative/quantitative changes in
landular secretion. The alterations of the normal lipid com-
osition in Meibomian gland secretions induce abnormalities
n tear ﬁlm composition and function thus inducing tear ﬁlm
vaporation and hyperosmolarity, the cause of evaporative dry
ye [4]. In fact, MGD  is likely to be the most common cause of
vaporative dry eye [2], and is responsible for approximately
0–60% of dry eye cases [5]. As a ﬁnal point, this condition may
esult in alteration of the tear ﬁlm, symptoms of eye irritation,
linically apparent inﬂammation, and ocular surface disease
6].
The physiological process involved in both conditions is
omplex and represents the interaction of multiple mech-
nisms such as tear ﬁlm hyperosmolarity, instability, and
ctivation of an inﬂammatory cascade that releases inﬂam-
atory mediators into the tears and this, in turn, can damage
he ocular surface epithelium [2,7]. MGD  and other subtypes
f dry eye diseases compromise tear ﬁlm stability and ocular
urface welfare, and share signs and symptoms in patients.
he dry eye workshop (DWES) recommends that any diag-
ostic protocol should include a classiﬁcation scheme that
ddresses the differential diagnosis of dry eye from other sub-
ypes and/or SOSD conditions. To this regard a classiﬁcation
f dry eye for practical clinical use has been also proposed
ased on three parameters such as etiopathogenesis, glands
nd tissues affected and disease severity [8].
Nevertheless, similar signs and symptoms frequently make
 speciﬁc discrimination between dry eye subtypes complex,
nd impose a difﬁculty in the selection of patients in basic and
pplied clinical research studies as well as clinical trials for
valuating the response to treatments. The correct interpre-
ation of the results obtained in this kind of studies may often
e hampered by outliers, or individuals whose behaviour is
ifferent from the rest of a speciﬁc group in which they have
een clinically classiﬁed.
Clinical proteomics is a promising practice with several
eatures that include high throughput, high sensitivity and
ow cost. Of all the proteomic approaches used for this pur-
ose, peptide and protein proﬁling has become a technique
ery close to clinical application [9]. Peptide/protein proﬁl-
ng is based on the detection of discriminatory patterns that
nable classifying and distinguishing between different study
opulations (e.g., patients versus healthy controls) and is cur-
ently being used as a clinical tool for the diagnosis of ovarian
ancer [9], microbial typing [10] or MS  imaging [11]. The pep-
ide/protein pattern is comprised of combinations of peaks in
he mass spectra plot that are deﬁned by the intensity of each
ignal on the y-axis, and the mass-to-charge ratio on the x-
xis. The changes in peptide/protein levels can be investigated
y looking for a subset of peaks on the spectrum that vary their ( 2 0 1 4 ) 206–215 207
intensities in different study populations or at different stages
of a disease.
Previous tear ﬁlm proteomic studies based on mass spec-
trometry (MS) have been useful in mapping the tear protein
proﬁles of patients and normal individuals. In tear ﬂuid, the
ﬁrst approaches have been done by surface enhanced laser
desorption/ionization (SELDI) mass spectrometry, combining
the selective retention capacity of peptides/proteins by dif-
ferent surfaces and mass spectrometry, and exploring the
diagnostic potential of this technique in patients with Sjö-
gren’s syndrome [12], dry eye patients [13], and the effect of
contact lenses on tear protein composition [14].
Given the limitations of SELDI-TOF for analytical per-
formance [15–17], the use of matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF) has been increasing due to higher resolution and
sensitivity and the possibility of coupling a solid phase extrac-
tion (SPE) protocol to enrich complex ﬂuids in a certain type
of analyte [18].
In this regard, MALDI-TOF proﬁling coupled with SPE has
been used to characterize low molecular weight (LMW)  pro-
teins in the diurnal variation of tears [19]. More  recently, our
group published a study on the inter-day and inter-individual
variability of normal tears and standardization of tear proﬁling
based on SPE-MALDI-TOF [20].
In this type of studies, however, instrument precision can
be reduced by variations in the triggering time from spectrum
to spectrum, small variations in the accelerating voltage, or
simply by random errors [21]. Therefore, in order to extract
the maximum biologically meaningful information from a
group of samples, aligning the spectra to ensure that features
occur at the same time position in all spectra being ana-
lyzed is recommended [22–24]. This is especially important
in multicentric studies where different MALDI-TOF spectro-
meters equipped with varying resolutions might be used and
consequently, the application of correction of spectra phase
variations enhances the reliability of results.
This study investigates the differences in tear pep-
tide/LMW protein proﬁles between three groups, dry eye, MGD
associated with DE and normal subjects in combination with
multivariate statistical analysis.
A variable penalty dynamic time-warping (VPdtw) based
alignment algorithm was implemented before using the
msProcess R package for mass spectra data pre-processing in
order to minimize bias due to phase variation. The compari-
son of the obtained proﬁles by different multivariate statistical
methods enabled identiﬁcation of a subset of speciﬁc peaks
which allow differentiation of groups. The method presented
here constitutes an objective tool that contributes to correct
discrimination of pathologies in cases with confusing or insuf-
ﬁcient signs; it enables the identiﬁcation of potential outliers
in clinical trials, and the monitoring of response to different
treatments.
2.  Materials  and  methods2.1.  Patients
A prospective case-controlled study was carried out, in which
93 patients were enrolled, 29 with dry eye (DE), 27 suffering
 m i c s208  e u  p a o p e n p r o t e o
Meibomian gland dysfunction (MGD) and 37 healthy control
(CT) subjects. All patients and normal subjects were recruited
from the Cornea Unit at the Instituto Clínico Quirúrgico de
Oftalmología (Bilbao, Bizkaia) and the Ophthalmology Depart-
ment at Cruces Hospital (Baracaldo, Bizkaia). The diagnosis
was based on clinical examinations including the Schirmer
I test with anaesthesia to measure only the basal secre-
tion, slit lamp examination of the lid margin and Meibomian
glands, ﬂuorescein staining, and subjective symptoms. Each
patient answered a modiﬁed “National Eye Institute Visual
Functioning Questionnaire 25” (VFQ-25) which includes some
statements about problems involving their vision or feel-
ing. Patients were classiﬁed as having DE if they had dry
eye symptoms, and Schirmer I test dynamics abnormali-
ties (≤5 mm/5  min), and ﬂuorescein staining according to the
Oxford scale. Patients were diagnosed as having MGD if they
presented symptoms including eyelid inﬂammation, and a
Schirmer I test result of >5 mm/5  min  and alteration in Mei-
bomian glands. In the control group, healthy subjects were
recruited who were not suffering from any ocular disease (no
allergic or atopic history), and presented Schirmer I test values
of >5 mm/5  min, no corneal ﬂuorescein staining or sensa-
tions of discomfort, and no evident eyelid inﬂammation. The
exclusion criteria included the presence or history of any sys-
temic or ocular disorder or condition (including ocular surgery,
trauma and disease) and patients presenting Sjögren’s syn-
drome. Contact lens users were also excluded to avoid any
possible interference with the interpretation of the results.
2.2.  Tear  sample  collection
Tear samples were collected with 10 L glass microcapillar-
ies (Blaubrand; Wertheim, Germany), by placing the capillary
close to the temporal lid margin of the eye and taking special
care not to touch the conjunctiva. Written informed consent
was obtained in accordance with the declaration of Helsinki
on Biomedical Research Involving Human Subjects. The study
was approved by the local ethics committee.
Tear samples were always collected in the morning, placed
in 1.5 mL  Protein LoBind Tubes (Eppendorf; Germany), cen-
trifuged at 4000 × g for 1 min  at 4 ◦C to remove any possible
cellular debris and immediately stored at −80 ◦C until analysis.
2.3.  Tear  sample  preparation  by  solid-phase  extraction
(SPE)
A puriﬁcation step was included prior to MALDI-TOF analy-
ses with the aim of enriching tear samples in peptides and
low molecular weight proteins. Ferromagnetic nanospheres
functionalized with C18 from the MB-HIC18 Magnetic Bead
Puriﬁcation Kit (Bruker Daltonics; Bremen, Germany) were
used to purify the tear samples following the manufacturer’s
instructions. All tear ﬂuid samples were progressively thawed
on ice, and subsequently 1 L of each sample was diluted to
10 L in MilliQ quality water. After the binding and wash-
ing steps (following the manufacturer’s instructions), each
puriﬁed sample was eluted in a single elution step with 5 L
acetonitrile (50% in deionized water). 3 ( 2 0 1 4 ) 206–215
2.4.  MALDI-TOF  mass  spectrometry
For MALDI-TOF target preparation, each puriﬁed sample was
diluted (1:10) in alpha-cyano-4-hydroxycinnamic acid (HCCA)
matrix (0.3 mg/mL  in ethanol:acetone (2:1) solution). In all
cases, 1 L of each diluted sample was spotted in quadru-
plicate onto an MTP  AnchorChip 600/384 TF plate using a
standard dried droplet method. Proﬁle analyses were per-
formed on an Autoﬂex III TOF/TOF Smartbeam spectrometer
with FlexControl 3.0 (Bruker Daltonics) data acquisition soft-
ware. Mass spectra were acquired in linear-mode geometry,
using the following settings: 1000–20,000 Th window, linear
positive mode, ion source 1: 20 kV, ion source 2: 18.5 kV, lens:
9 kV, pulsed ion extraction of 120 ns, high gating ion sup-
pression up to 500 m/z. Ionization was achieved by irradiation
with a solid state 360 nm pulsed laser operating at 66 Hz (30%
attenuator). All spectra were obtained randomly over the spot
surface (5000 shots ﬁred per spot) using an automatic method
in a mass range between 1 and 20 kDa. Mass calibration was
performed externally using the Protein Calibration Standard I
(Bruker Daltonics)
2.5.  Data  processing  and  statistical  analysis
After data collection, pre-processing steps were applied to
each raw spectrum in order to extract putatively meaningful
features before presentation to feature selection, clustering,
and classiﬁcation algorithms. These steps included a baseline
correction based on local regression (LOESS), alignment of the
spectra by VPdtw using the VPdtw package [25] from R statis-
tics software [26]. For VPdtw implementation, a penalty based
on dilation or moving local maximum over a window of 850
consecutive registered data points were applied. Peak identiﬁ-
cation and clustering by multiresolution decomposition (MRD)
applying maximal overlap discrete wavelet transform with a
signal to noise threshold of 10 and a m/z precision of 0.001 were
performed. Finally total ion count normalization was applied.
The last three pre-processing steps were performed using the
msProcess R-package [27].
Once all pre-processing steps had been completed, includ-
ing a warping procedure to reduce phase variation, the data
was conﬁdent enough to perform the statistical analyses
required to obtain clinical relevant information.
Subsequently, the data matrix of peak intensities con-
taining the aligned peak list was extracted and used for
multivariate statistical analysis purposes. Feature subset sub-
traction was performed by stepwise discriminant analysis to
obtain the most signiﬁcant attributes in the differentiation
between groups with a p-value < 0.01 cut-off.
The clustering of the samples was performed by means
of a nonlinear iterative partial least squares (NIPALS) data
exploratory technique. In addition, using features subtracted
by stepwise discriminant analysis, machine learning approach
based on multilayer perceptron neural network was per-
formed to assess statistical model accuracy for the correct
classiﬁcation of problem samples. Machine learning algorithm
was trained by the selected peaks and, in order to assess the
performance of the learner, 10-fold random sampling was car-
ried out with 70% of the samples as a training set and the
remaining 30% were considered as test set. This test set was
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Table 1 – Demographical data.
CT DE MGD
n Age (years) n Age (years) n Age (years)
Male 13 38.00 ± 9.59 10 59.29 ± 18.03 11 45.36 ± 18.72
Female 24 41.35 ± 14.12 19 48.27 ± 11.18 16 58.92 ± 14.38
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CT, control; DE, dry eye; MGD, Meibomian gland dysfunction.
sed to evaluate the success of the algorithm for the classi-
cation of samples to which the learners had not previously
een exposed. Machine learning and clustering statistics were
arried out using TANAGRA v1.4.44 statistical software using
he default parameters established by the software [28].
.6.  SDS–PAGE  and  protein  identiﬁcation  by
ALDI-TOF/TOF
or protein peak identiﬁcation, 20 g of total tear protein
as resolved in 12% sodium dodecyl sulphate–polyacrylamide
el electrophoresis (SDS–PAGE). After electrophoresis, pro-
eins were stained with 0.1% Coomassie Brilliant Blue R-250.
rotein bands from approximately 14–17 kDa were excised
nd subjected to an in-gel digestion protocol consisting of
ithiothreitol reduction at 56 ◦C (10 mM,  20 min) followed by
odoacetamide alkylation (55 mM,  20 min  in a dark environ-
ent), and ﬁnally trypsin incubation (12.5 g/L) overnight at
7 ◦C. After digestion, peptides were extracted with ammo-
ium bicarbonate (25 mM)  and triﬂuoroacetic acid (0.1% in
ater). Peptide mass ﬁngerprinting (PMF, based on MS  data)
nd peptide fragment ﬁngerprinting (PFF, based on the MS/MS
ata from some of the peptides located in the PMF  and frag-
ented by LIFT-TOF) analyses were carried out by spotting
eptides using the dried droplet method (0.5 L sample + 0.5 L
CCA matrix) on a GroundSteel 384 target (Bruker Daltonics).
he mass spectrometer was used in the same way as described
bove, but in reﬂectron mode for PMF  and Lift mode for MS/MS.
he routine included collecting 1400 scans for PMF and 2000
cans for MS/MS  (400 for parent ion selection and 1600 for frag-
ent ions). Identiﬁcation was performed with Swissprot v56
s a database using a MASCOT 2.1 search algorithm with toler-
nces of 50 ppm for PMF  and precursor ions and 0.7 Da for frag-
ent ions. Both MS (PMF) and MS/MS  (PFF) data is combined
nto the same search to obtain the best identiﬁcation possible.
.  Results
.1.  Patients
nalyses of subjective symptoms reported on the modiﬁed
FQ-25 questionnaire indicated that DE patients mainly com-
lain of a gritty sensation, dryness, and a burning sensation,
nd referred to the use of ocular lubricants. MGD patients
eferred to redness and swelling, and the presence of sensory
ymptoms (itching, irritation and soreness). Healthy subjects
id not mention any of these symptoms. In general, the DE
nd MGD  patients presented mild to moderate forms of the
iseases. The groups were gender-matched. Thus, the male vs.52.07 ± 13.54 27 53.40 ± 16.15
female relation in each group was 34.5% male vs. 65.5% female
for DE, 41% male vs. 59% female for MGD, and 35% male vs. 65%
female for CT. Demographical data are shown in Table 1.
3.2.  Solid-phase  extraction  (SPE)  for  tear  sample
enrichment
All tear samples were treated with HIC18 Magnetic Beads
(Bruker Daltonics) for peptide and protein enrichment in the
range of 1000–20,000 Da as described previously [20]. The SPE
puriﬁcation allowed high quality spectrum proﬁles suitable for
peptide/LMW protein proﬁling analysis.
The enriched tear samples were subsequently analyzed by
MALDI-TOF, and the resulting raw spectra generally showed a
high abundance of peak signals, mainly in the 1000–4000 Th
range, and less presence of peak signals above 10,000 Da.
Due to the complexity of the mass spectrometry outcome, a
pseudo-gel view of all spectra obtained from analysis of the
DE, MGD and CT groups was used to simplify data visualiza-
tion and comprehension (Fig. 1). In this type of representation,
the x-axis shows the mass/charge (m/z) ratio, the y-axis is the
running spectrum (each with four technical replicates) and the
peak intensity expressed in arbitrary units (a.u.). In general,
the spectra showed a high abundance of peaks in the peptide
region up to 4 kDa and several masses up to 18 kDa.
3.3.  Spectra  alignment  and  peak  detection
Before performing peak detection and statistical analysis, the
raw data obtained from MALDI-TOF assays were subjected to a
spectra alignment procedure by VPdtw to adjust any possible
drifts introduced by the instrument. As result of this align-
ment, the peaks were synchronized in all spectra and thus
were ready for peak assignment and clusterization (Fig. 2).
The peaks were detected by spectra decomposition using
an MRD method applying a maximal overlap discrete wavelet
transform (MODWT). Finally, a peak-clustering protocol was
applied to the different clinical groups, giving a total panel of
236 features.
3.4.  Feature  subset  and  clustering
Features that contained discriminatory information for clas-
sifying the three groups of this study were determined by
selecting subsets of peaks using stepwise discriminant anal-
ysis. This analysis conﬁrmed that the spatial features with
the best ability to discriminate between DE, MGD  and CT
subjects were peaks 1096, 1231, 1702, 1835, 2508, 2524, 2576,
3557, 4345, 4775, 5781 and 17,467 (Fig. 3). The dimensionality
210  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 206–215
Fig. 1 – Peptidome/proteome proﬁle virtual gel of tear samples processed with the solid-phase extraction (SPE) protocol,
representing the mass/charge (m/z) ratio (x-axis) for each spectrum acquired (y-axis). The intensity of the signal is
represented as a grey intensity scale corresponding virtually to the z-axis. In all the cases, each tear was spotted in
y andquadruplicate in order to verify the technique reproducibilit
of the dataset was reduced by nonlinear iterative partial
least squares (NIPALS) analysis using only the 12 most dis-
criminant variables indicated above. The separation obtained
between the groups revealed a clustering of the samples
not only between controls and pathological conditions but
also between both diseases, indicating that these 12 features
(peaks) provide good accuracy for discrimination of DE, MGD
and CT (Fig. 4). A spatial separation of DE and MGD  patho-
logical groups from the CT group was clearly observed and a
differentiation between disease groups was also evident. Two
outliers were identiﬁed, one belonging to the CT group and the
other to the MGD  group.
Fig. 2 – Illustration of 3100–3500 Da alignment window showing
variable penalty dynamic time warping synchronization process enhance statistical validity.
3.5.  Machine  learning  and  statistical  model  generation
The generation of predictive models for use as classiﬁers was
explored by performing 10-fold random sampling of 70% of
the whole data using machine learning approach based on
artiﬁcial neural networks. The obtained classiﬁer was sub-
sequently validated using the remaining 30% of data. As a
result of this analysis, good classiﬁcation power was achieved
using the 12 most signiﬁcant peaks panel as conﬁrmed ROC
curves analysis (Supplementary Figure), with a percentage of
correct assignment (%CA) of 89.3% including the three groups
in the study. Correct assignment represents the percentage of
 reference and query spectra before (A) and after (B) a
. The good performance of the alignment can be seen.
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Fig. 3 – Average mass spectra of tear samples processed with solid-phase extraction (SPE) protocol for dry eye (DE),
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amples correctly classiﬁed using the panel of 12 discriminat-
ng peaks compared to clinical diagnosis.
.6.  Identiﬁcation  of  mass  spectra  peak  by  SDS–PAGE
nd MALDI-TOF/TOFDS–PAGE of total tear protein was performed to isolate and
dentify discriminant peaks using MALDI-TOF/TOF mass spec-
rometry. The gel obtained is shown in Fig. 5. The two clearest
ands below the 20 kDa marker were excised and digested
ig. 4 – Nonlinear iterative partial least squares (NIPALS) analysi
tepwise discriminant analysis. The spatial ordering and the sep
alues of the variables included in the analysis is apparent. In th
ndividual from each group, and good separation between the th
GD  outlier can also be observed and are indicated by correspon
riangles: CT group).wing the informative peaks obtained by stepwise
with trypsin. Identiﬁcation using a combination of PMF  + Lift
(MS/MS) resulted in lipocalin 1 (Uniprot: P31025) for the upper
band indicated in Fig. 5, and lysozyme C (Uniprot: P61626) for
the lower band (data not shown). These results were coher-
ent with the mass spectra obtained in the 6000–20,000 Th
window shown in Fig. 3, where the two main peaks corre-
sponding to 17,429 and 14,664 Th correlate with the results
(lipocalin 1: 17,445 Da and lysozyme C: 14,700 Da, indicated
in Fig. 5C), within the instrument tolerance limits in linear
mode.
s using the most discriminant variables obtained by
aration produced between the samples as a function of the
is representation, each of the points represents one
ree groups can be seen. The presence of one CT and one
ding arrows (squares: DE group; circles: MGD  group;
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Fig. 5 – Identiﬁcation of informative peak. (A) SDS–PAGE of a tear sample extracted with C18. Bands remarked were  excised
and digested for protein identiﬁcation by mass spectrometry analysis. (B) MS/MS  (Lift-TOF) spectra corresponding to peptide
GLSTESILIPR of lipocalin-1 with a Mascot score of 86 (statistical signiﬁcance above 31). Lipocalin-1 sequence showing this
peptide in red, and the peptides matched by PMF  are indicated in green. (C) Mass proﬁle of C18 extracted tear showing the
masses attributed to lipocalin-1 and lysozyme C. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of the article.)4.  Discussion
The tear ﬁlm study of ocular pathologies requires methodolo-
gies sensitive enough to allow the use of a just few microliters
of sample as starting material, especially in pathologies like
dry eye syndrome where the tear amount may be reduced.
Tear ﬁlm is a bioﬂuid that covers the eye surface, keep-
ing it wet, nourished and lubricated. The foundation of the
proﬁling use for diagnostic purposes is based on the fact that
basal tear peptidome and proteome reﬂect changes depend-
ing on the pathological stage and the abundance of peptides
and/or proteins of different natures are part of pathophysio-
logical and defense processes. This pathological stage is, in
turn, induced by disturbance in any of the lacrimal function
unit (LFU) component, including lacrimal system, the ocular
surface and its accessory glands and their neural intercon-
nections [2]. In fact, it has been recently reported that dry eye
patients present both structural and functional alterations of
subbasal corneal nerves and that those changes are found to
be related to the severity of dry eye [29].Several efforts have been pursued lately to get clinically
valuable information based on tear proteomic data and the
role of proteins in disease [30–34]. However, those studies have
mainly explored the disease of interest independently and
are distant from high throughput application in clinical stud-
ies. Possibly from these studies, SELDI technology might be
closer to this kind of application. In this regard, Tomosugi
et al. explored the potential use of SELDI to analyze pro-
teomic patterns in Sjögren’s syndrome [12], and Grus et al.
used it for the analysis of tears from patients with dry eye
[13]. However, it has been postulated that solid phase extrac-
tion in combination with MALDI-TOF analysis overcomes the
limitations of SELDI analysis [9]. Consequently, this study
applied a SPE-MALDI-TOF method for the analysis of tear
proteomics by comparing the peptide and small proteome
proﬁles of three different conditions, DE, MGD  and healthy
controls.Given that both pathological conditions are closely related
to each other, complicating the analysis of samples, high qual-
ity results in terms of peptides/protein proﬁles and separation
of groups based on these proﬁles are required.
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For an optimal proﬁling analysis, the data obtained from
ass spectrometry must undergo several pre-processing
tages to precisely identify the location of peaks in the
ass/charge ratio. In practice, instrument precision may be
educed by variations in the triggering time from spectrum to
pectrum, small variations in the accelerating voltage, or sim-
ly by random errors [21] and this may lead to incorrect peak
ssignment and deﬁcient pattern recognition based on mass
pectra. It has been reported that the accuracy of peak loca-
ion in MALDI-TOF is within 0.15–0.3% of the mass (m/z) value
35]. Therefore, it is essential to align or synchronize spectra
o ensure that features occur at the same time position in all
pectra being analyzed. After this step, features of biological
nterest can be clearly revealed by multivariate analysis.
In this context, the alignment of spectral data has been
tudied extensively in the MS  ﬁeld [22–24]. There are vari-
us approaches to aligning MALDI-TOF data, including the
se of frequent calibration [36], clustering or re-binning
37–40], cross-correlations [41], minimizing entropy [42] or,
ore  recently, self-calibrated warping in SELDI-TOF [43]. A
rerequisite of the majority of all of these methods is that
he peaks must ﬁrst be identiﬁed. However, as synchroniza-
ion errors may appear in the peaks throughout the whole
pectrum, the corrections applied to the complete time range
hould provide greater precision and better alignment results
21]. This study used an alignment stage prior to the detec-
ion and assignment of peaks that involved VPdtw [25]. To
ur knowledge this is the ﬁrst work in which VPdtw align-
ent procedure has been applied to MALDI-TOF data and
ore  speciﬁcally to tear ﬁlm analysis. This method was used
ith practical purposes to improve predictive model accuracy
hroughout the study. In-depth studies of the best method for
rocessing MALDI-TOF data have been extensively reported by
ther groups [43–45]. However, this study tested different pre-
rocessing techniques for spectra data in order to ﬁnd which
nes best ﬁtted DE, MGD  and CT MALDI-TOF proﬁles. This
eans, the same MALDI-TOF raw spectra were subjected to
arping and non-warping procedures. There was a remark-
ble improvement in the classiﬁcation accuracy from 71.4% to
5.7% of correct assignment when including a warping step in
he MALDI-TOF data pre-processing pipeline (data not shown).
Due to the complexity of DE and MGD  diseases and the
mplication of different biological processes in the evolution
f these pathologies, a panel of peaks obtained by feature
ubtraction methods can offer more  precise discrimination
etween diseases than discrimination based on a single peak.
upervised feature subtraction performed by stepwise dis-
riminant analysis produced a data reduction from 236 to
2 signiﬁcant peaks. The use of this panel of 12 peaks in
onjunction with multivariate statistical analysis allowed dis-
riminating the study groups with a high percentage of correct
ssignment. A clear separation of the control group from
athological groups is easily seen. Besides, a spatial separation
etween the DE and MGD  groups is also observed, even more
iscrete than in the case of the control group. In addition, it is
lso possible to identify possible outliers. More  speciﬁcally, in
ur analysis we were able to identify two possible outliers as
epicted in Fig. 4 by arrows. It is evident that one control sub-
ect is out of the main group and a review of the clinical record
evealed that this subject did not present signs or symptoms ( 2 0 1 4 ) 206–215 213
of disease, however the shift from the main control group
towards the MGD  group in an intermediate position between
those groups, suggests possible early onset of the disease even
in an asymptomatic phase, and the necessity for follow-up of
the patient. Furthermore, the proﬁle of a MGD patient sug-
gests that this patient behaved more  as a DE patient since is
located within this group. In this case, even if this patient was
recruited as MGD,  a coexistence with DE could explain this
result, fact that often occurs in daily clinical practice. All these
results delineate peptide/protein proﬁling as a promising tool
to aid clinical practice.
Once good separation of the groups was observed by data
exploratory techniques, machine learning algorithm based on
neural networks was used to build predictive model for dis-
tinguishing between the DE, MGD and control groups. In any
statistical modelling process validation of the model is a cru-
cial step. The effectiveness of the model was 10-fold evaluated
by random sampling using the panel of 12 peaks obtaining a
89.3% of correct assignment when comparing all three groups
included in the study.
In order to identify some of the discriminant peaks, 20 g of
tear protein from a control subject was resolved in SDS  gel. The
resulting SDS–PAGE correlates well with the masses observed
in the 10,000–20,000 Da range (Fig. 3), with two  main peaks
located at 17,429 and 14,664 Th, and the corresponding dou-
ble charged masses (8705 and 7331 Th, respectively) (Fig. 5C).
Identiﬁcation by combined PMF + Lift (MS/MS) resulted in LCN1
(Uniprot: P31025, Mm 17445 Da) for the upper band, and
lysozyme C (Uniprot: P61626, Mm 14,700 Da) for the lower
band. The mass of 17,445 attributed to LCN1 is located in the
feature subset analysis as a deregulated marker peak, where a
reduction of signal peak is observed under pathological condi-
tions. Interestingly, LCN1 is a major protein in tears and has a
variety of functions, including regulation of tear viscosity, lipid
binding, and antimicrobial and anti-inﬂammatory activities,
among others. This protein has already been reported to be
deregulated in tears of dry eye [13,33,46], Sjögren’s syndrome
[47] and MDG  patients [46].
However, LCN1 has been mentioned as a potential marker
in different dry eye and non-dry eye diseases, being apparently
associated with non-speciﬁc inﬂammation, inﬂammation
induced by therapy, or stress conditions [48–51], thus implying
that the speciﬁcity of lipocalin as a single protein for dis-
criminating pathologies seems to be limited. It is clear that
in multifactorial diseases one unique biomarker is normally
not informative enough to explain all the complex signalling
and functional networks that are altered in a pathological con-
dition. In our particular study it is clear that lipocalin 1, or any
other discriminative peak by itself, lacks enough diagnostic
power to discriminate DE and MGD  in dry eye groups.
Therefore, these very promising results should be
expanded with even more  samples of each condition,
and further efforts to identify informative peptides by com-
bining alternative mass spectrometry approaches such as
off-line MALDI-TOF/TOF and/or nano liquid chromatography
(nLC) together with on-line tandem mass spectrometry would
help in consolidating and framing the data obtained in a
physiological scenario.
In summary, this study applied solid phase extraction
methods in combination with MALDI-TOF peptide and low
 m i c s
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molecular weight protein analysis. In addition, the application
of a warping procedure and multivariate statistical analysis of
the resulting spectra allowed differentiation between DE, MGD
and control, the three conditions studied, using a panel of 12
informative peaks.
To the best of our knowledge, this is the ﬁrst time two
related ocular surface diseases have been analyzed by tear
peptide/LMW protein MALDI-TOF proﬁling, and effectively dif-
ferentiated.
This study constitutes a sensitive, fast method that allows
for the possibility of high throughput analysis and easy clas-
siﬁcation of patients into appropriate groups according to the
peptide/protein proﬁle provided by the panel of 12 peaks found
being discriminative. Just like in other health areas where
sample proﬁling is already applied for diagnostic purposes, we
suggest that combining this strategy in ophthalmology with
routine clinical protocols such us questionnaires and clinical
tests (Schirmer I test, tear breakup time, staining of the cornea
and conjunctiva, among others) would help in better diagno-
sis, prognosis and monitoring of aqueous-deﬁcient dry eye and
MGD.
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